GlassScriptPhysician profile
William Stix Jonas
NPI 1962443051
$27,951.74
in general payments reported to CMS, 2019-2025
67 companies · $5,822 in 2025
The $5,822 reported for 2025 was more than what 83% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,478 · 2020: $2,432 · 2021: $2,036 · 2022: $2,219 · 2023: $5,271 · 2024: $1,694 · 2025: $5,822.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,389 · Food and Beverage: $5,323 · Education: $76.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,388.83 |
| Food and Beverage | $5,322.76 |
| Education | $76.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $8,178.12 | 2019-2025 | |
| Beigene USA, INC. | $3,441.28 | 2020-2025 | Brukinsa, Tevimbra |
| Astrazeneca Pharmaceuticals LP | $2,545.40 | 2019-2025 | Enhertu, Lynparza, Tagrisso |
| E.R. Squibb & Sons, L.L.C. | $2,177.16 | 2019-2025 | Opdivo |
| Tg Therapeutics, INC. | $1,665.00 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,622.50 | 2019-2025 | Alunbrig, Ninlaro, Fruzaqla |
| R-Pharm US LLC | $1,334.61 | 2019 | |
| Pfizer INC. | $584.38 | 2019-2025 | |
| Genzyme Corporation | $459.08 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $453.86 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Abbvie INC. | $358.67 | 2019-2025 | |
| Genentech USA, INC. | $356.18 | 2019-2024 | Tecentriq, Rozlytrek, Alecensa |
| Seagen INC. | $331.64 | 2019-2023 | Adcetris, Tukysa, Tivdak |
| Eisai INC. | $314.54 | 2019-2025 | |
| Daiichi Sankyo INC. | $298.67 | 2023-2025 | Enhertu, Datroway |
Show all 67 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $295.14 | 2019-2023 | Vectibix, Nplate, Xgeva |
| Boston Scientific Corporation | $236.78 | 2020-2023 | Spyscope Ds, Exalt Model D |
| Gilead Sciences, INC. | $225.46 | 2021-2025 | Trodelvy |
| Glaxosmithkline, LLC. | $172.05 | 2023-2025 | Ojjaara, Zejula, Jemperli |
| Intera Oncology, INC | $152.62 | 2023 | Intera 3000 Implantable Pump |
| Rigel Pharmaceuticals, INC. | $150.66 | 2019-2024 | Rezlidhia, Tavalisse |
| Astellas Pharma US INC | $149.49 | 2019-2024 | Padcev |
| Pharmacyclics LLC, An Abbvie Company | $149.09 | 2019-2023 | Imbruvica |
| Janssen Biotech, INC. | $144.74 | 2020-2025 | Rybrevant, Darzalex, Tecvayli |
| Gt Medical Technologies, INC | $140.00 | 2023 | Gammatile |
| Biocompatibles, INC. | $139.41 | 2019 | |
| Stryker Corporation | $137.31 | 2025 | Optablate |
| Legend Biotech USA INC. | $124.34 | 2024-2025 | Carvykti |
| Array Biopharma INC | $108.04 | 2019-2025 | Braftovi, Mektovi, Lorbrena |
| Celgene Corporation | $103.80 | 2023-2025 | Pomalyst, Opdualag, Reblozyl |
| Incyte Corporation | $100.59 | 2023-2025 | Jakafi, Monjuvi, Zynyz |
| Epizyme, INC. | $99.82 | 2021-2023 | Tazverik |
| Intuitive Surgical, INC. | $95.80 | 2021 | |
| Janssen Pharmaceuticals, INC | $93.07 | 2019-2023 | Xarelto |
| Adaptive Biotechnologies Corporation | $72.29 | 2023-2025 | Clonoseq |
| Regeneron Healthcare Solutions, INC. | $60.64 | 2019-2024 | Libtayo |
| Kite Pharma, INC. | $57.37 | 2021-2023 | Yescarta |
| Bayer Healthcare Pharmaceuticals INC. | $54.86 | 2019 | |
| Beone Medicines USA, INC. | $54.24 | 2025 | Tevimbra, Brukinsa |
| Adc Therapeutics America, INC. | $54.14 | 2022 | |
| Servier Pharmaceuticals LLC | $49.59 | 2023-2025 | |
| Emd Serono, INC. | $49.27 | 2023-2024 | Bavencio |
| Genmab U.S., INC. | $42.99 | 2023-2025 | Epkinly |
| Mirati Therapeutics, INC. | $39.93 | 2023 | Krazati |
| G1 Therapeutics, INC. | $38.84 | 2023 | Cosela |
| Azurity Pharmaceuticals, INC. | $33.51 | 2025 | Danziten |
| Karyopharm Therapeutics INC. | $29.57 | 2020-2022 | |
| Mckesson Specialty Care Distribution, LLC | $28.81 | 2019 | |
| Iovance Biotherapeutics, INC. | $26.55 | 2025 | Amtagvi |
| Jazz Pharmaceuticals INC. | $26.54 | 2024 | |
| Pharmaessentia USA Corporation | $24.66 | 2025 | Besremi |
| Exelixis INC. | $21.76 | 2024 | Cabometyx |
| Geron Corporation | $20.51 | 2025 | Rytelo |
| Stemline Therapeutics INC. | $20.06 | 2023 | Orserdu |
| Syndax Pharmaceuticals, INC. | $19.98 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.15 | 2019 | |
| Tempus Ai, INC | $18.68 | 2025 | Xt Cdx |
| Lilly USA, LLC | $18.00 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $17.70 | 2019 | |
| Puma Biotechnology, INC. | $17.05 | 2022 | |
| Coherus Oncology, INC. | $16.82 | 2022 | |
| Portola Pharmaceuticals, LLC | $14.59 | 2019 | |
| Acrotech Biopharma INC. | $14.26 | 2024 | Beleodaq |
| Foundation Medicine, INC. | $13.86 | 2019 | |
| Cti Biopharma Corp. | $12.64 | 2022 | |
| Octapharma USA, INC. | $12.39 | 2022 | |
| Dova Pharmaceuticals | $11.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Jonas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.